Celljevity
About
What does Celljevity do?
Celljevity is a longevity company focused on reversing biological aging through cellular rejuvenation technology and AI-powered health optimization. They offer the Prometheus Therapy, a patented process that restores aged cells to a youthful state without genetic modification, and complement it with a Digital Twin Platform that uses multi-omic data and AI modeling for personalized longevity. The company aims to make these advanced therapies accessible to a broader population.
What is Celljevity's valuation?
StartupHub estimates Celljevity's effective valuation at $252.0M (range $157.5M to $378.0M, 16% confidence), based on comparable companies in the sector.
How much funding has Celljevity raised?
Celljevity has raised a total of $63M in funding. The most recent round on record is Series A.
Where is Celljevity headquartered?
Celljevity is headquartered in Beverwijk, Netherlands.
When was Celljevity founded?
Celljevity was founded in 2018.
What industry does Celljevity operate in?
Celljevity operates in Longevity, Biotech, HealthTech, Cellular Regeneration, AI Diagnostics, Digital Twin.
What is Celljevity's current status?
Celljevity's current operating status is: Inactive.
Provider-supervised peptide therapy, NAD+ support, and cognitive enhancement for cellular renewal, recovery, and healthy aging.
Longevity and metabolic health platform offering personalized insights and interventions.
An AI-native platform that helps individuals plan their entire 100-year life by integrating health, money, work, and purpose.
AI-powered platform for personalized health and longevity.
A free, instant biological-age mirror that tells you how old your body really is, with no signup required.
AI-powered longevity and wellness insights based on aging hallmarks.
An entrant is a company tagged Longevity whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.